The widespread use of clhronic dialysis and renal homotransplantation, while prolonging the lives of patients with chronic renal failure, have concomitantly resulted in the appearance of severe disorders of calcium and phosphorus metabolism and disabling renal osteodystrophy (retardation of growth and dwarfism, osteitis fibrosa, rickets or osteomalacia and, at times, osteosclerosis). Furthermore, it is apparent that the usual conservative measures, i.e., giving high doses of calcium, correcting acidosis with alkali, restricting phosphates, and giving phosphate-binding antacids orally, frequently fail to correct hypocalcemia and osteodystrophy or to reduce symptoms. Some of these measures, including chronic dialysis, may actually worsen abnormalities in osseous structure and metabolism as well as contribute to deposition of calcium salts in the soft tissue. Thus, abnormalities in calcium and phosphorus metabolism present a major obstacle to the rehabilitation of the patient with chronic renal failure. Stanbury and Lumb1 have stressed the need for interpreting the biochemical abnormalities in the plasma in relation to the osseous changes.
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DISCUSSION OF CHRONIC RENAL FAILURE
The present report is a revised and expanded formulation ( Fig. 1 ) of divalent ion metabolism and osseous lesions in chronic renal failure.2 From the available data, a unified approach to these disorders is presented. The formulation and discussion are based on the following generally accepted concepts:
1.) The secretion of parathyroid hormone (PTH) is stimulated by a decrease in the free calcium ion (Ca++)* concentration of the blood perfusing the parathyroid glands, and there is no conclusive evidence that decreased amounts of magnesium in the plasma or increased concentration of inorganic phosphate per se alters hormone secretion. ' 2.) Parathyroid hormone regulates the level of Ca++ in body fluids by enhancing the liberation of skeletal calcium, increasing the renal clearance of PO4-, decreasing the renal clearance of calcium,' and increasing the intestinal absorption of calcium.
3.) For any given level of parathyroid gland activity or the metabolic state of the individual, an increase in the concentration of PO4= in the extracellular fluid (ECF) causes a decrease in the concentration of Ca+ +.'-a-' This is primarily due to a change in the skeletal-ECF equilibrium that results in a net movement of calcium into the bones and the establishment of a new steady state with a higher serum PO4. and lower Ca+ +.
4.) Vitamin D deficiency or resistance to this vitamin causes a defect in the intestinal absorption of calcium in response to need, defective mineralization of cartilage and the organic matrix of bone, leading to rickets and/or osteomalacia, and impaired action of parathyroid hormone on the skeleton.' Under these circumstances a greater-than-normal amount of parathyroid hormone is necessary to maintain the Ca++ concentration of body fluids and may lead to secondary hyperplasia of the parathyroid glands. There is no evidence that the vitamin D-resistant or deficient state alters the renal response to PTH.
5.) Hyperplasia of the parathyroid glands with increased secretion of PTH occurs in chronic renal failure." Vitamin D resistance (Fig. 1, A) At some stage during the course of chronic renal failure a moderate-tosevere resistance to the action of vitamin D on the skeleton and GI tract develops." -9' . There is evidence to suggest that these metabolic abnormalities may appear long before there is serious azotemia and at times when renal failure is relatively mild (glomerular filtration rate [GFR] CHRONIC RENAL DISEASE WITH The observation that patients with chronic renal failure are resistant to vitamin D was first emphasized by Liu and Chu in 1943.9 They found that very large doses (greater than the equivalent of 100,000 U/day) were frequently needed to correct the hypocalcemia, and a bone lesion indistinguishable from rickets or osteomalacia. They concluded that the metabolic and osseous abnormalities were not due to vitamin D deficiency per se, but represented "an interference with the action of the vitamin conditioned by renal insufficiency."9 Yendt, Connor, and Howarde demonstrated that plasma from uremic patients interfered with the in vitro calcification of rachitic cartilage whereas normal plasma did not. This suggests the possibility that a humoral factor may be responsible, or at least contribute to the vitamin D resistant state.** Dent, et al." and Stanbury, et al.' 8 have also amply demonstrated this resistance, although its exact cause is unknown. It could result from a circulating or tissue inhibitor of vitamin D or an alteration in vitamin D metabolism (enhanced destruction or inactivation). Stanbury and Lumb found that defective absorption of calcium from the gastrointestinal (GI) tract persists until extremely high levels of vitamin are attained in the plasma.' Since their studies," 8"' we have treated the resistant hypocalcemia and osteodystrophy of chronic renal failure with vitamin D and confirmed their observation that large doses, usually in excess of 50,000 U and at times as high as 200,000 to 300,000 U/day, are necessary. It has not been conclusively demonstrated that there is a good correlation between the degree of renal failure and the amount of resistance to the vitamin D effect.
Once this resistant state has developed, (Fig. 1, A) it results in defective reabsorption of calcium and, secondarily, PO4--from the GI tract in response to need,""89'1' and as impaired response of the skeleton to vitamin * In the present review we are not including for discussion primary disorders of tubular dysfunction, such as congenital renal tubular acidosis, Fanconi's Syndrome, cystinuria, etc., which may be associated with phosphate "wasting," vitamin D resistance, and osteomalacia. The abnormalities are the consequence of the intrinsic renal tubular disorder rather than the presence of renal failure and azotemia. It is reasonable to conclude, however, that if renal failure does develop in these tubular syndromes, the metabolic abnormality of chronic renal failure will be superimposed upon the basic consequences of the tubular defect. ** Pyrophosphates (P205) are present in microgram and milligram quantities, respectively, in plasma and urine of normal subj ects. These compounds markedly increase the solubility of calcium phosphate salts and through this mechanism they may interfere with the calcification of tissues at normal concentration of these salts.""8
It is possible that pyrophosphates may be present in increased amounts in the plasma of uremic patients. Their presence would interfere with in vitro calcification of rachitic cartilage.
D per se and, as a consequence, to PTH.1"0"9 From empirical observations and the experimental studies, one can conclude that these processes need not be impaired in an "all-or-none" manner. There may be striking differences in the extent of defects among patients with comparable degrees and duration of azotemia.' 8, 9, 11 and unpublished observations While large doses of vitamin D are necessary to effect the optimum absorption of calcium in these patients, the deficiency can be compensated for in some patients by a very large intake of calcium, usually in excess of 3 gm/day. We have noted this in patients ingesting 10 to 20 grams of calcium carbonate per day, as have Clarkson, McDonald, and de Wardener.2' However, when calcium ingestion is diminished, as it often is in patients with chronic renal failure, and the gastrointestinal absorptive defect is significant, the losses of calcium in the feces may cause definite calcium deficiency. The latter may be an important factor in the bone' atrophy (osteoporosis) that at times is a significant component of renal osteodystrophy. There is convincing evidence that calcium deficiency per se causes osteoporosis2' rather than osteomalacia or osteitis fibrosis. The failure of a normal vitamin D effect on the skeleton must, in time, result in rickets (in the young) or osteomalacia, and impair the skeletal action of PTH necessary to maintain the Ca++ concentration in extracellular fluid. 10 Stanbury and Lumb1 report that the hypocalcemia of renal failure, particularly when the major osseous lesion is osteomalacia, is unresponsive to doses of Lilly parathyroid extract of 800 U/day. Evansone demonstrated that the i.v. administration of 1-USP U/kilo/hour over a 10-hour period had (change < 0.7 mg. per 100 ml.) no effect on serum calcium in chronic renal failure if the initial level was below 7.5 mg. per 100 ml. Those with serum calcium above this level responded to the PTH infusion with increases of 1 to 2.5 mg. per 100 ml. The unresponsive patients had the lowest initial calcium levels. This failure of response was not due to the already high circulating levels of PTH, for Evanson19 found that patients with primary hyperparathyroidism (high endogenous hormone levels) increased their serum calcium further during the PTH infusion. Also, Berson and Yalow'5 found no correlation between the serum calcium and the amount of the PTH (radio-immunoassay) in the plasma of chronic renal failure patients.
Serumt calcium and phosphate (PO4-) (Fig. 1, B with chronic phosphate depletion as manifested by a low 24-hour excretion of P04--. This is probably due to poor intake, impaired absorption, and, questionably, the deposition of P4O-in soft tissues. Hyperphosphatemia is not usually observed before the stable GFR decreases to 25 (Fig. 2) , an indication of the low 24-hour excretion of PO4--. 2.) The degree and acuteness of lean tissue breakdown, i.e., surgical or medical trauma, acute starvation, and glucocorticoid or tetracycline administration may all cause breakdown of lean tissue. The intracellular organic phosphates liberated will be metabolized to PO4--, and because of the severe renal failure the PO4m-concentration in the blood will rise until formation and excretion are again equal. 3 .) The calcium content of the diet. Liu and Chu9 observed that when calcium intake was increased by 700 to 1,500 mg. per day, a significant decrease in the PO4-concentration in the plasma occurred in each patient. This was usually, but not always accompanied by a rise in plasma calcium ( Figure 4 , taken from their paper, demonstrates that increasing phosphorus intake from approxi-Divalent ions in renal failure I KLEEMAN, BETTER, MASSRY, MAXWELL mately 500 mg. to 1,000 mg/day caused a definite increase in serum PO4= and a fall in serum calcium concentration. A significant metabolic response to vitamin D, with a marked increase in the intestinal absorption of calcium and PO4:-, may fail to cause a significant rise in the concentration of serum calcium if the enhanced absorption of P04-causes greater hyperphosphatemia. This is clearly illustrated in Figure 5 . Stanbury has questioned the inverse relationship because he found no correlation between the total plasma calcium and the P04-concentration in a large population of unselected uremic subjects (Fig. 6 ). However, when Ca++ concentration is plotted against diffusible PO4= in unselected uremic patients ( Fig. 7) , a significant inverse correlation is demonstrated; but it must be stressed that because of the significant rise in the complexed fraction of the diffusible calcium in chronic renal failure ( Fig. 8 ),27 the amount of calcium in plasma may not reflect accurately what is happening to the concentration of Ca++ ion even when plasma protein concentration and therefore protein-bound calcium appears to be normal.*
The exact chemical nature of the organic and inorganic anions, with the exception of S04 and PO.--forming the diffusible complexes with calcium in chronic renal failure, is unknown, but the complexed fraction may reach 25 to 30%o of the total serum calcium; normally the complexed diffusible fraction represents 7 to 10%o (Fig. 8) . ' 2 It has been our experience and that of others (M. Parfitt, Univ. of Queensland, Australia, personal communication), that the inverse relationship between total calcium and inorganic P04-in the plasma is much more apparent when azotemia follows acute renal failure. This suggests that when time does not permit the type of metabolic adjustments observed in chronic renal failure, the inverse relationship between Ca++ and P04--will be more apparent. However, it should be noted that in our diagrammatic scheme ( Fig. 1, B ) the effect of a rise in PO4-on the Ca+ + concentration is represented by an arrow of intermediate thickness, indicating that this relationship is a significant but probably not the most important cause of the reduced Ca++ concentration in chronic renal failure. In fact, we have on occasion noted that the P04-concentration can be reduced from hyperphosphatemic levels to low normal by restricting phosphorus and giving aluminum hydroxide jel with minimal, if any, improvement in the hypocalcemia. An example is shown in Table 2 . This emphasizes the importance * Occasionally mild hypercalcemia has been observed in severe chronic renal failure. It is apparent that before one can conclude that a true hypercalcemic state (a rise in free calcium ion concentratior (Ca++) above normal exists, an analysis of Ca++ must be made. Fig. 1, B) .
As renal failure progresses, there is a significant decrease in the total serum calcium and, more important, the Ca++ concentration (Figs. 8, 9 ). It is apparent from the above discussion that because of the elevation of the complexed diffusible fraction, the total plasma calcium measured in the uremic patient underestimates the magnitude of the "true" hypocalcemia. It is frequently difficult in any given patient to explain adequately the presence, absence, or magnitude of hypocalcemia. The authors feel that the most important factors responsible for true hypocalcemia are the degree of elevation of the P04= concentration for any given "metabolic setting" of the patient and, more important, the impaired responsiveness of the skeleton to the high level of circulating PTH, a consequence primarily of resistance to vitamin D (Fig. 1, A & B) . If osteitis fibrosa is the predominant bone lesion in any given patient with chronic renal failure, and this can be accepted as indicating skeletal responqiveness to the excess circulating PTH despite vitamin D resistance, then the degree of hypocalcemia is inversely proportional to the responsiveness of the skeleton to PTH.' It is also possible that the vitamin D resistant state, independent of its role in PTH responsiveness, may contribute to the skeletal defect responsible for the hypocalcemia (Fig. 1, A) . Finally, the defect in absorption of calcium from the GI tract with the development of true calcium deficiency may also contribute to the amount of hypocalcemia for any given "metabolic setting" of the patient (Fig. 1, A & B) .
Parathyrcid structure and function
There is no doubt that the progressive hyperplasia and hypertrophy of the parathyroid glands in chronic renal failure is due to the prolonged hypocalcemia.' The increased mass may at times reach enormous pro- hormone excretion comparable to those in severe primary hyperparathyroidism (personal communication). It will be noted in Figure 1 that a dotted arrow connects the original reduced renal mass and GFR with the increased circulating level of PTH. Recent data suggests that the kidney may be important in the inactivation of PTH,U " and in preliminary experiments (Table 3) we have confirmed these findings.' Furthermore, if a significant proportion of the secreted PTH is excreted in the urine in an active form, one would expect that as renal mass decreased, clearance of hormone would also decrease. Therefore, the less the excretion and inactivation of PTH for any given rate of secretion the higher would be the steady state circulating level.
If the skeleton is responsive to the latter, the Ca++ concentration of the blood will return toward normal and this concentration, through negative "feed back," should inhibit further excess secretion of hormone from the glands. Unfortunately, the constellation of metabolic events that caused the original sustained decrease in Ca++ concentration (Fig. 1, A & B) , continues to maintain some degree of hypocalcemia (reduced Ca+ +) despite the hypersecretion, and the parathyroid glands continue to grow. The increased mass of functioning parathyroid tissue may well create a vicious cycle in which it requires a greater than normal Ca+ + concen- tration to shut off hormone secretion or at least to prevent hypersecretion.1' The large mass of parathyroid tissue becomes relatively autonomous without the development of an actual adenomatous change in one or more of the hyperplastic glands. Recently Gittes and Radde' have carried out elegant experiments which may be considered the experimental counterpart of this situation. They transplanted 20-80 normal rat parathyroid glands to the thigh muscles of normal recipient rats. This caused a sustained hypercalcemia for at least 25 days, or experimental hyperparathyroidism in the recipient animal. The authors concluded that the mass of normal parathyroid tissue was so great that the sensitive "feed back" inhibition of parathyroid secretion that normally follows a minimal rise in 18 Volume 40, August, 1967 Divalent ions int renal failure KLEEMAN, BETTER, MASSRY, MAXWELL Ca++ concentration was unable to shut off hormone secretion and resulted in sustained hypercalcemia. These experiments suggest that the greater the degree of over-all hyperplasia of the parathyroid glands in chronic renal failure the more relatively "autonomous" they will become, i.e., they will continue to secrete excessive amounts of PTH even though the plasma Ca++ is returned to, or even above, normal. These levels of serum Ca++ seem to be produced by the skeletal response to the hormone, or by exogenous calcium loads, and/or effective doses of vitamin D.* However, the magnitude of this "autonomous" function probably varies greatly from patient to patient, being primarily dependent on the degree of hyperplasia of the parathyroid glands.
The suppressibility of the parathyroid glands, as measured by the reduction in the PO4-/creatinine clearance ratio during and after a calcium infusion, may vary from relatively normal to non-suppressible. Berson and Yalow' infused calcium into two uremic patients and noted a decrease of 75 and 80%'o, respectively, in the concentration of PTH in their plasma within one hour. Impaired or absent suppressibility in a given patient with chronic renal failure may indicate that the patient is prone to develop "autonomous, secondary hyperparathyroidism" (see Fig. 1 , C) after transplantation or to show increasing manifestations of secondary hyperparathyroidism and metastatic calcification during a chronic dialysis program.
We have found that when some patients with severe chronic renal failure are ingesting large amounts of CaCO3, i.e., 20 grams/day with or without vitamin D, they may rapidly develop significant hypercalcemia, which usually disappears within a few days of stopping the high calcium intake. In these patients hypercalcemia secondary to "excess" vitamin D may also disappear rapidly after stopping the vitamin. These observations suggest that the homeostatic inhibition of parathyroid secretion does not occur in a normal manner in some chronic renal failure patients as their hypocalcemia is corrected (Fig. 1, C) .
We stated earlier that a rise in plasma PO4m--for any given "metabolic setting" would cause a decrease in Ca+ + concentration. Conversely, a significant reduction in PO4, concentration should contribute to a rise in Ca+ +. In normal subjects, marked hypophosphatemia due to dietary P04-restriction and aluminum hydroxide (AIOH3) ingestion does not cause * It could be postulated that the secretion of the calcium lowering hormone of the thyroid (thyrocalcitonin) is defective in chronic renal failure; however, until a physiologic role for this hormone can be demonstrated in humans, we prefer to conclude that abnormal increments in serum calcium in chronic renal failure are due to the massive hyperplasia of the parathyroid glands in association with a probably decreased inactivation and excretion of PTH. parathyroidectomy, and subsequent calciferol therapy on the serum calcium and phosphorus in a patient with severe secondary hyperparathyroidism. The concentrations represent those found just prior to a given dialysis. When the serum calcemia was at its highest, the immediate post-dialysis serum phosphorus was 3.0 mg. per 100 ml. The phosphorus concentration in post-dialysis serum prior to the Aludrox ranged between 5 and 6 mg. per 100 ml.
while visiting Auckland Hospital in Auckland, New Zealand, the senior author was shown a case of chronic renal failure with severe secondary hyperparathyroidism, osteitis fibrosa, and metastatic calcification where the patient gradually developed mild hypercalcemia after many months of hemodialysis. Because of continued hyperphosphatemia the patient was placed on Al(OH)3 therapy for two months. During this period frank hypercalcemia (14.5 mg. per 100 ml.) developed as P04--fell to lownormal (Fig. 11) . Subsequent parathyroid surgery demonstrated four Divalent ions in renal failure I KLEEMAN, BETTER, MASSRY, MAXWELL large diffusely hyperplastic but not adenomatous glands.* Recently, a patient in our chronic dialysis program developed increasingly severe nietastatic vascular calcification. This was so extreme in her digital vessels that necrotic changes in the tips of her fingers and toes were observed. Serum calcium was near, but always slightly below, normal and her serum PO4-between dialyses averaged 8 to 12 mg. per 100 ml. X-rays of her skeleton showed typical osteitis fibrosa. Subsequent to a most successful renal transplantation (post-operative creatinine clearance 80-100 cc/min.), she developed frank hyperparathyroidism with hypercalcemia, hypophosphatemia and a very high PO4-/creatinine clearance ratio (50%). The vascular calcification and the digital ischemic changes became much more severe. Prior to p)arathyroid surgery, PO4--clearance did not decrease during or after a calcium infusion that increased serum calcium to 14 mg. per 100 ml. At surgery 3-3/4 diffusely hyperplastic parathyroid glands, each 2-3 cm. in length, were removed. The cure of her hyperparathyroidism has resulted in significant improvement in her digital circulation and healing of the ischemic ulcers. We cite this and the previous examples as cases of "autonomously" functioning hyperplastic parathyroid glands. Comparable non-adenomatous glands have been removed in the treatment of severe "autonomous" secondary hyperparathyroidism developing during chronic hemodialysis and after renal transplantation." s 3 Each of the patients who developed a picture of primary hyperparathyroidism after renal transplantation had normal-to-high-normal serum calcium and markedly elevated PO4-prior to surgery.
Renal clearance of P04-In Fig. 1 , C we have indicated that the sustained rise in circulating parathyroid hormone causes an increase in the renal clearance of P04--within the limits imtposed by the degree of renal failure. Although the U. V. of P i i r e.
--e q s absolute clearance of --is obviously reduced, i.e., requires a higher plasma PO4,-to excrete the normal daily phosphate load, the PO4--/GFR (creatinine or inulin) clearance ratio in most instances increases as renal failure progresses, at times exceeding 100% of the calculated filtered PO4:- (Fig. 12) ratio are: 1.) secondary hyperparathyroidism. There is no evidence that the vitamin D resistant state of chronic renal failure interferes with the action of PTH on the nephron. 2.) The increased filtered load of P04-per nephron, which is secondary to the hyperphosphatemia, and in certain renal diseases such as chronic pyelonephritis, an increased GFR per residual nephron. Others have suggested that this increasing ratio as renal failure progresses is the main factor preventing the rise in plasma PO4--until less than 25 o of normal renal function remains.' Earlier in discussion 22 Volume 40, August, 1967 Divalent ions in renal failure KLEEMAN, BETTER, MASSRY, MAXWELL we stressed the role of non-renal factors determining the plasma PO4-concentration. In Fig. 2 it is evident that in an unselected population of patients with chronic renal failure the PO4-/GFR clearance ratio does not always rise as renal failure progresses despite the fact that many of these patients have normal, or near normal plasma PO4= concentrations. There is no doubt that the low P04-intake and absorption (fecal: urinary P4O high) contributes to the sustained relatively low clearance ratio despite the marked secondary hyperparathyroidism. Effective vitamin D (Fig. 13) . In fact, it should be stressed that in far advanced kidney disease (less than 20%o of normal GFR) the high P04=/GFR ratio becomes progressively less important in determining the PO-concentration in the plasma. Nothing could emphasize this more than the prompt fall in plasma P04:, despite the simultaneous fall in P04EE clearance in these patients (Fig. 3) , that follows parathyroidectomy.
Skeletal responsiveness to PTH, nietastatic calcification and osteodystrophy. When the skeleton is capable of responding to the excess circulating PTH, the result will not only be higher free Ca+ + ion concentration, but also higher PO4,n concentrations in the body fluids, the latter imposed by the severe renal failure. The (Ca++) (PO4-) product will inevitably rise to abnormal levels. Under these circumstances (Fig. 1, D) , we will be confronted with the desperate situation of the patient's increasing osteitis fibrosa leading to a progressive shift of bone mineral to soft tissues, resulting finally in clinically evident imietastatic calcification. XVe stress "clinically evident" because it is most likely that there is a marked increase in soft tissue deposition of calciuml phosphate salts long before they are evident clinically or even seen with the usual technique of light microscopy. The contribution of excess soft tissue deposition of calcium salts to organ dysfunction is unknown. It is quite possible that excess calcium deposition in renal parenchyma can contribute to further deterioration in renal function in chronic renal failure patients* (Fig. 1, D) . A systemic study of the soft tissue content of divalent ions in chronic renal failure is most needed. It is our impression that the intolerable pruritis observed in some of the patients in our chronic dialysis programii is due not to the uremia per se, but to the deposition of calcium salts in dermal structures. Both the New Zealand patient described above and a patient of ours had intolerable pruritis which was not corrected by two hemodialyses per week. Total parathyroidectomiiy without a basic improvement in their underlying renal disease, caused complete relief of their pruritis within one week of surgery.
It should be clear that any procedure that contributes to a positive * A careful review of the references to parathyroidectomy in chronic renal failure'' 8t 2}0 29 ', $5 does not suggest that cure of the severe secondary hyperparathyroidism has resulted in appreciable improvement in renal function as measured by BUN, NPN, or serum creatinine. However, it is well known that with changing protein content of the diet, or any alteration in production of creatinine, these determinations may not be an accurate reflection of glomerular filtration and of course they give no indication of the state of tubular function. Therefore all chronic renal failure patients undergoing parathyroidectomy should have careful pre-and postoperative studies of renal hemodynamics and tubular dysfunction. calcium balance without simultaneously correcting the basic disorder(s) of divalent and osseous metabolism will aggravate the metastatic calcification.
In Figure 1 vitamin D resistant state, osteomalacia rather than osteitis fibrosa will be the predominant skeletal lesion. Under these circumstances the Ca++ concentration in the blood will be lower for any given elevation of PO4-;
in fact, as demonstrated by Stanbury, et al.,' and discussed above, the P04= concentration will also be lower in this group (Fig. 14) . On the basis of bone histology (biopsy or autopsy), Stanbury and Lumb1 have separated the chronic renal patients with osteodystrophy into those with either predomninant osteitis fibrosa, or osteomalacia lesions, with the respective biochemical picture illustrated in Figure 1 , D. However, it must be stressed that if the skeleton in renal osteodystrophy could be studied in toto, one would probably see a mixed picture of osteomalacia, osteitis fibrosa, osteoporosis and even osteosclerosis.'8 "'S In any given case one or another of these lesions may predominate. The magnitude of vitamin D resistance and the responsiveness of the skeleton to PTH will vary greatly from patient to patient and with time and degree of azotemia in a given patient. A vivid example of this was recently afforded in one of our chronic dialysis patients. This patient after many months in dialysis began to complain of increasing bone pain. X-rays disclosed increasing demineralization of her skeleton. She had a spontaneous fracture of her clavicle, with minimal soft tissue calcification. She was treated with large doses of vitamin D (more than 100,000 U/day). This caused a remarkable clearing of her osseous pain and questionable improvement in skeletal mineralization; however, increasing metastatic calcification, including skin, corneal, and conjunctival deposition, and phalangeal lesions of osteitis fibrosa appeared. Osteomalacia was improved, but secondary hyperparathyroidism became worse. This patient has most recently been operated on with the removal of three diffusely hyperplastic parathyroid glands 4 to 6 times larger than normal; a fourth gland could not be located. It is of considerable interest that skeletal pain may clear completely with vitamin D despite evidence that osteitis fibrosa is not improving and actually getting worse. Physicians following patients closely with various types of metabolic bone disease have long been aware that osteomalacia is a much more painful disorder than is osteitis fibrosa. In fact, one is often amazed at how severe the latter can be with minimal skeletal discomfort. Immobilization, calcium deficiency per se,2' and chronic protein depletion are probably the main causes of the actual osteoporosis (bone atrophy) component of renal osteodystrophy. In patients with chronic renal failure over the age of 50 post-menopausal, idiopathic or "senile" osteoporosis may contribute to the skeletal abnormality.
Osteosclerosis: The most unusual skeletal appearance in renal osteodystrophy is "osteosclerosis." The latter, in most cases, is more an X-ray than a pathologic entity, being referred to as "increased bone density." Histologically, the latter may represent an increased amount of normally mineralized bone, a greatly increased amount of bone with less than normal mineralization, or a normal amount of bone with greater-than-normal mineralization.
In the studies reviewed,"'9 the first two were primarily responsible for the description of "osteosclerosis" observed in renal osteodystrophy. Garner and Ball40 carried out critical quantitative studies of bone mass and bone density or the amount of mineralized (or calcified) and unmineralized cancellous bone in a measured area, in a standard site in the iliac crest of normal subjects and 18 with chronic renal azotemia. They found that in most cases the osteosclerosis is due to the accumulation of unmineralized bone (osteoid) in association with an increased total bone mass. The mineralized bone mass is usually within normal limits but in four cases was actually increased. Varying degrees of osteitis fibrosa and irregular marginal erosion of the mineralized bone was evident in 15 of the cases. Presumably, osteoid accumulates because of the increased osteoblastic activity, and because of the resistance of osteoid to osteoclasis. In none of the studiesg could "osteosclerosis" be correlated with any specific pattern of change in the serum levels of calcium, PO,-, or alkaline phosphatase.
The increased osteoblastic activity may be due to the chronic effect of the excess circulating PTH acting on a skeleton made resistant to the actions of the hormone by the uremic state, the result being a greater degree of osteoblastic activity for any given degree of osteoclasis.< ' Ball and Garner' have further suggested that the occasional case of hypermineralization, or an. increased amount of mineralized bone in renal osteodystrophy may result from an excess production of abnormal, more readily calcifiable bone matrix (woven) rather than the normal lamellar pattern.
The role of metabolic acidosis While chronic acidosis can bring about a significant loss of the acid soluble calcium (carbonates) of the skeleton,' its contribution to the histologic lesions of renal osteodystrophy is extremely difficult to assess. Jaffe, et al.' demonstrated that ingestion of large amounts of ammonium chloride (0.4-1 gm/kg) for 11 weeks did not produce skeletal lesions in the oldest dogs (18 months) maintained on normal calcium intake. They found that the younger the animal (down to 3 months) and the lower the calcium intake, the more severe was the bone pathology. Their illustrations of the gross characteristics of the skeleton showed extensive bone atrophy in the most severe cases. Their description of the microscopic changes suggests osteitis fibrosa of a minimal degree in the latter. No osteomalacia or rickets was observed. Unfortunately, in none of these studies were there August, 1967 000"" than normal (Fig. 16) . It can be seen that this ratio, in general, increases as renal failure progresses. This pattern is quite similar to the renal handling of many ions (Na+, K+, Mg++, Cl, PO4-) as functional renal n-iass decreases in chronic renal failure. It can be reasonably well correlated with the increased osmotic and, particularly, Na+ "load per nephron" (Fig. 16) .
It is our impression that the calcium clearance/GFR ratio in chronic renal failure is greater in chronic pyelonephritis, or diseases with relatively more severe tubular than glomerular injury, than in the primary "glomerular" disorders, i.e., glomerulonephritis (Fig. 17) . It is in the former that we also see the greatest "salt wasting." In view of the extremely close interrelationship between sodium and calcium excretion in normal animals and humans,'9 it is quite possible that such. factors as increased osmotic load and GFR per nephron that contribute to the salt wasting in chronic renal failure,' exert a comparable effect on calcium. We are unable to correlate the absolute hypocalciuria or the clearance. ratio with the steady state concentration of plasma diffusible calcium or the calculated filtered load of calcium. There is, however, a significantly positive correlation with the complexed diffusible fraction of the total plasma calcium' when clearance ratios are determined from random timed urine collections in the stable chronic renal failure patient.
It seems most unlikely that the reduced renal mass and the reduced filtered load of calcium per se can be a major cause of the absolute hypocalciuria of chronic renal failure. For that reason we have represented this interrelationship by a broken line on the left-hand side of Figure 1 . Evidently, although Ca clearance/GFR ratio is greater than normal in chronic renal failure (Fig. 16) , the residual nephrons must be attempting to conserve calcium within the limits'imposed by the solute and' Na+ load/ iiephron. In other words, the Ca'clearance/GFR ratio would be even higher if the residual nephrons were not 'maintaining the absolute hypocalciuria. The question can be asked what factors'are responsible for the attempt at renal conservation of calcium by the residual nephrons in chronic renal failure? It is known that when the renal function is normal, PTH,' calcium deficiency per se, vitamin D deficiency (or true primary resistance), and high-PO4-intake (with or without increased serum PO4-) all may cause a reduction in the renal clearance and excretion of calcium. It is presently thought that PTH decreases the renal clearance of calcium by a direct effect on-the nephron.7 It is not known how calcium and/or vitamin D deficiency or high PO4-intake* cause the kidney to conserve calcium maximally. In part it may be due to the physiologic secondary hyperparathyroidism which occurs in these states. Suffice it to say that in chronic renal failure all of these factors probably contribute to the absolute hypocalciuria, as indicated in Figure 1 , E. Positive calcium balance brought about by large oral loads of calcium, or by intravenous infusions of calciun without a basic correction of the underlying metabolic defects (Fig. 1) , will, as they increase plasma calcium, increase the clearance and excretion of calcium in chronic renal failure patients.9' 0' unpublished observations It is of great interest that the pattern of increase in Ca clearance/GFR ratio that occurs in chronic renal failure patients, as their plasma calciuln is raised by infusion of CaCl2,, is remarkably similar to that of normal subjects receiving similar infusions while under the influence of two-hourly injections of parathyroid extract.7 It is important to note that when large doses of vitamin D bring about a marked improvement in osseous metabolism, strongly positive calcium balance due to enhanced absorption of calcium from the GI tract, and a significant correction of hypocalcemia, urinary calcium may remain very low despite an unequivocal rise in the filtered load of calcium (Fig. 18) .``This would indicate a further reduction in calcium clearance as the beneficial effect of the vitamin D on the skeleton (new mineralization and bone accretion) somehow signals the kidney to retain as much calcium as possible for osseous needs. To the authors' knowledge there is no clear-cut evidence that vitamin D per se has a direct effect on the renal clearance of calcium.' It is apparent from the above discussion that the alteration in the renal handling of calcium, as nephron destruction progresses, is secondary to the over-all derangement in divalent ion and osseous metabolism and it does not contribute to the development of the osteodystrophy or hypocalcemia. However, a severe reduction in renal mass may remove a safety valve factor that contributes to the homeostatic prevention of hypercalcemia associated with excessive calcium ingestion and/or vitamin D intoxication. The ability of the normal kidney to develop significant hypercalciuria without appreciable hypercalcemia is * While there is no doubt that high PO4-intake in normal subjects almost invariably causes a reduction in urinary calcium and positive calcium balance, probably by shifting the equilibrium of calcium phosphate salts "back into the skeleton," it is not known whether the hyperphosphatemia independent of high PO4M intake can contribute to the hypocalciuria of chronic renal failure. In two patients with severe renal failure (creatinine clearance 4 and 15 cc/min) maintained on low P04m intake and antacids for 7-8 days so that their serum P04EE fell 2.5-3.0 mg per 100 ml., the severe hypocalciuria (< 20 mg/24 hours) was not altered. However, it may be necessary to restrict P04--intake considerably longer than 7-8 days in the chronic renal failure patient to demonstrate the hypercalciuric effect of PO4.E: depletion. Note that despite the positive calcium balance and the marked rise in serum calciuml (and filtered load), the urinary calcium did not increase. (From Stanbury.) 8 an important mechanism for clearing excess calcium from the blood when the buffering capacity of the skeleton is blunted by disease (i.e., osteitis fibrosa), or when excessive bone resorption is occurring. An elegant experimental example of this safety valve role of the kidney has been brought to the senior author's attention by Dr. M. Parfitt, Dept. of Med., Univ. of Queensland Medical School, Australia. He has confirmed that chronic administration of thiazide diuretics can cause significant hypocalciuria in normal subjects and patients with idiopathic hypercalciuria.' While studying the effect of thiazides on the hypercalciuria that frequently accompanies successful vitamin D treatment of hypoparathyroidism, he noted that a patient developed frank hypercalcemia when the urinary calcium was significantly reduced by thiazide ingestion and that the hypercalcemia promptly disappeared when the diuretic was stopped and hypercalciuria reappeared. He subsequently realized that this patient had mild vitamin D intoxication and was probably on the verge of developing hypercalcemia. It is common knowledge that patients with hypercalcemic disorders of any etiology may develop much more severe hypercalcemia if pre-renal azotemia occurs from salt and water depletion. Therefore in chronic renal failure the loss of the renal safety valve may predispose, under certain circumstances, to the more rapid development of hypercalcemia.
Magnesium: Although alterations in magnesium metabolism do not appear to contribute to the osteodystrophy, it seems appropriate to refer to magnesium in any discussion of divalent ion metabolism in chronic renal failure. In our own studies we were surprised to find how rarely hypermagnesemia was present in azotemic patients. No alterations in the protein (non-diffusible) to non-protein bound fraction of plasma magnesium was detected (Fig. 8) ; in fact, if the patient had been eating poorly for a number of days it was not unusual to see mild hypomagnesemia with the continued urinary excretion of significant anmounts of miagnesium (Mg+ + "wasting syndrome").
Investigations of magnesium and calcium clearance in patients with chronic renal failure has demonstrated why significant elevations of plasma magnesium are unusual. In normal subjects the clearance of diffusible magnesium is usually 2 to 2.5 times the simultaneously measured calcium clearance, or approximately 4-6%o filtered magnesium." As renal failure progresses, this ratio (Mg/Ca clearance) increases (Fig. 19 ) and magnesium clearance may reach 60-70% of the filtered magnesium. It is readily apparent that despite marked reduction in renal mass the absolute clearance of magnesium may remain very close to normal and therefore plasma magnesium will also remain normal. This rise in Mg clearance/GFR ratio as renal failure progresses resembles much more closely the altered renal handling of potassium rather than that of calcium. Therefore we see the kidney in chronic renal failure trying to conserve calcium maximally while rejecting magnesium. We recently had the opportunity to see a patient with severe renal failure secondary to pyelonephritis, who entered the hospital with bizarre CNS symptoms and a serum magnesium of 0.85 mg. per 100 ml. or approximately 11/3 of normal. His history indicated extremely poor food intake for many weeks prior to admission. On admission his urine was free of magnesium. As repletion occurred with intravenous and intramuscular administration of magnesium salts, urinary Mg rose rapidly despite continued hypomagnesemia. When his serum magnesium had returned to normal (2.66 mg. per 100 ml.), the Mg++/ GFR clearance ratio was 0.5. It seems reasonable to conclude that his very poor intake of magnesium, coupled with the continued renal wasting of this ion, caused the severe magnesium depletion syndrome. Of additional interest in this patient was the severe hypocalcemia (5.0 mg. per 100 ml.) also present on admission. With magnesium repletion the serum calcium rose to 8.5 mg. per 100 ml. and remained at this level without supplemental calcium or appreciable improvement in renal function. Heaton, et al.5M demonstrated the magnesium deficiency in man predisposed to hypocalcemia. They suggest that this deficiency interferes with calcium release from bone.
The exact mechanisms responsible for the magnesium "wasting" of chronic renal failure is unknown. However, Chesley, et al.> and Barker, et al. concluded that a reabsorptive Tm (maximal rate of tubular reabsorption in mgs/min.) for magnesium does exist and that it is very close to the normal concentration of filtered magnesium. Therefore, any slight increase in the plasma concentration of magnesium or in the filtered load per nephron in the chronic renal failure patient would quickly "saturate" the reabsorptive capacity of the remaining nephrons and the additional filtered magnesium would appear quantitatively in the urine. This concept requires experimental confirmation. The only time we have observed significant hypermagnesemia in chronic renal failure is when excessive amounts of magnesium are infused or the patient ingests large quantities of an antacid containing magnesium.' In our patients with chronic renal failure we were unable to demonstrate any specific interrelationship between total and diffusible plasma magnesium and calcium.
THERAPY
If the symptomatic and/or corrective therapy of the disorders of divalent ion metabolism and osteodystrophy in cronic renal failure is to be of reasonable value to the patient, the physician must be aware of the general concepts discussed in the preceding paragraphs and outlined in diagrammatic fashion in Figure 1 . It will become increasingly apparent that while correcting one biochemical abnormality in this constellation the therapist may be seriously aggravating another. Therefore, each patient must be critically evaluated before introducing any long-term form of corrective therapy and re-evaluated at appropriate intervals to convince oneself that what was previously good for the patient has not become bad.
It is almost axiomatic in the treatment of chronic renal failure that any reversible pre-renal or post-renal components should be corrected. This correction should be of benefit in ameliorating the sequence of events (Fig. 1) set in motion by the reduction in renal mass and renal hemodynamics. Once these reversible factors are corrected we are left with the stable chronic azotemic patient, usually with varying degrees of hypocalcemia and hyperphosphatemia, with or without clinical evidence of osteodystrophy. Our fundamental over-all approach should be to: 1.) return the skeleton to normal; 2.) correct, and prevent soft tissue deposition of calcium salts, and 3.) maintain the free Ca++ ion and P04m-concentrations in the blood as near normal as possible. It is questionable whether mild degrees of hypocalcemia (7-8 mg. per 100 ml.) or hyperphosphatemia (less than 5.5 mg. per 100 ml.) per se require specific treatment unless they are 36 Volume 40, August, 1967 Drivalent ions in renal failure I KLEEMAN, BETTER, MASSRY, MAXWELL associated with significant radiologic, pathologic (biopsy), or clinical evidence of osteodystrophy. A decision as to the introduction of large-dose vitamin D therapy must rest on the presence of evident osseous pathology and the ease with which moderately-severe-to-severe hypocalcemia can be corrected with more conservative measures. Hyperphosphatemia can be corrected by rigid phosphate restriction and the administration of alkaline earth antacids that bind PO.I--in a non-absorbable form.' As the P04-concentration in the plasma returns to normal, a significant rise in calcium concentration may occur. This will be hastened by the simultaneous administration of liberal quantities of calcium salts. CaCO3 (20-30 gm/day) may supply the calcium ion, "bind" P04-in the GI tract and correct mild acidosis." unpublished observations It is apparent from examination of Figure 1 and the earlier discussion, that the correction of hypocalcemia by this conservative approach will depend on the magnitude of the vitamin D resistant state and the skeletal responsiveness to PTH (Fig. 1) . It must be stressed that calcium "loading" and an elevation in the free Ca++ concentration that is not accompanied by a significant reduction in PO4--will result in a further rise in the already elevated (Ca+ +) (PO4-) product.2" unpublished observations This could only lead to more soft tissue deposition of calcium salts if the fundamental skeletal abnormality is not improved. True hypercalcemia can be caused by high calcium ingestion per se. This would be due to defective "buffering" capacity of the skeleton and the loss of the "safety valve" function of the kidney. Finally, although chronic dietary PO4--restriction and antacid administration can cause a significant reduction in PO4= concentration and therefore in the (Ca++) (PO4-) product and even at times correct overt metastatic calcification if the serum P04-can be returned to normal5'8 (also, unpublished observations, and F. H. Epstein, personal communication), one must be aware that this therapy lowers plasma PO4--by causing phosphate depletion. The latter may already be present in a patient with severe renal failure and the treatment would make it worse. Phosphate depletion per se may seriously interfere with normal mineralization of the skeleton, increase the loss of calcium from bone to ECF and soft tissues, cause a significant negative calcium balance' and aggravate osteoporosis and osteomalacia.
It is appropriate to mention at this time that one always hopes that any technique that returns the Ca++ concentration of the plasma to normal will shut off the excess secretion of PTH and prevent the undesirable consequences of secondary hyperparathyroidism (Fig. 1, C & D) . Unfortunately, some degree of "autonomous" hypersecretion may continue in many cases and under these circumstances if the skeleton can respond to PTH, or our treatment (vitamin D or dialysis) improves its responsiveness, we may simply aggravate osteitis fibrosa, soft tissue calcification, and predispose the patient to hypercalcemia. It may be possible to determine which patients with chronic renal failure have "autonomously" functioning parathyroid glands and therefore plan the most acceptable therapeutic approach. If after returning the plasma PO---to a normal level with alkaline earth gels, mild but definite hypercalcemia develops, PTH hypersecretion is continuing. If hypercalcemia does not develop, the patient may be given a 4-6 hour infusion of 1.5 to 2.5 gin. of Ca++ ion as CaCl2 while following serum Ca++ and PO4-and the PO4,/GFR clearance ratio at 4-hour intervals for 24 hours. If the clearance ratio decreases 50% or more 12 to 24 hours after starting the calcium infusion, it probably indicates reasonable suppressibility of the hypersecreting glands."' Conversely, a failure of the PO4, clearance to fall indicates autonomously functioning parathyroid glands.'9 It would be ideal to measure directly the change in the plasma concentration of PTH (radio-immunoassay), or in the renal excretion of extractable PTH'8 during and after the standard infusion of calcium. It should be noted that we recommend infusion of 1.5 to 2.5 gm.
of calcium ion (25-40 mg/kilo) rather than the usual gram dose utilized when renal function is normal. It has been our experience that when renal osteodystrophy is present the lower dose of calcium may be temporarily, but rapidly "taken up" by the skeleton, and questionably the soft tissues, and little or no hypercalcemia will develop to inhibit parathyroid secretion.
In those cases where vitamin D therapy seems most indicated (severe skeletal demineralization, overt rickets or osteomalacia in association with low plasma calcium and minimal hyperphosphatemia (Fig. 1) , it may produce a remarkable amelioration of bone pain, return the calcium concentration to normal and correct rickets, osteomalacia, and secondary hyperparathyroidism (osteitis fibrosa).1"8,9,11 Although the underlying renal disease is not corrected, the patient may be markedly rehabilitated. As shown in Figures 6 and 14 be "shut off." The entire osteodystrophy syndrome may be corrected. Under these circumstances any calcium salts that have left the skeleton and been deposited in soft tissues should now return to the healing hungry bones. If, however, an optimum vitamin D response occurs in a patient with "autonomously" functioning parathyroid glands, a new difficulty is created. The osteomalacia component of the osteodystrophy may be corrected and bone pain disappears but, because the skeleton now becomes responsive to the excess circulating PTH (Fig. 1, A) a tendency towards hypercalcemia appears and progressive osteitis fibrosa develops. This is usually accompanied by increasing metastatic calcification (eyes, skin, joints, vessels, etc.), particularly if the patient is also ingesting large amounts of calcium and alkali or receiving them from repeated chronic dialysis. There may be no way to correct the syndrome short of stopping the vitamin D and allowing the pre-vitamin D state to re-develop, or by total parathyroidectomy. The latter seems by far the most sensible. The symptomatic improvement of the patient may be overwhelming; the osteitis fibrosa may heal and the calcium salts deposited in a most destructive manner in the soft tissues will return to the skeleton. High dose vitamin D therapy, of course is continued to treat the surgical hypoparathyroidism and prevent the redevelopment of osteomalacia or rickets.
If the skeleton of the untreated patient with severe chronic renal failure is relatively responsive to the very high levels of circulating PTH (Fig. 1,  C) , he may first appear with near-normal or normal total plasma calcium despite severe hyperphosphatemia. Bone X-rays will frequently show definite osteitis fibrosa, especially subperiosteal bone resorption in the phalanges and there may or may not be evident soft tissue calcification. As mentioned above, P04= restriction and/or vitamin D treatment in this patient may cause frank hypercalcemia with all its adverse consequences. Even though this patient may be in over-all negative calcium balance, if metastatic calcification is marked, it may be necessary, at least temporarily, to rigidly restrict calcium intake or "remove" calcium from the body by dialysis. It is evident that the latter is only a necessary "stop gap" measure, pending parathyroidectomy to prevent the inexorable destructive process. Once parathyroidectomy is carried out, high-dose vitamin D therapy can be introduced to treat the residual osteomalacia and hypoparathyroidism. If the action of PTH on the skeleton could be blocked by medical means, it would be possible to treat this type of patient without parathyroid surgery. The calcium lowering hormone, thyrocalcitonin, could prove to be such a medical treatment for it can directly antagonize the calcium mobilizing effect of PTH and inhibit bone resorption.' It certainly should be utilized experimentally in this clinical setting.
Finally, what is the effect(s) of engrafting recurrent or chronic peritoneal or hemodialysis upon the basic metabolic disorders shown in Figure 1 ? By correcting azotemia per se, it is quite possible that there may be temporary responsiveness of the skeleton to the excess circulating PTH. Simultaneously, in most cases, the PO4--concentration will decrease, the free Ca++ concentration will increase, and acidosis will be corrected. As mentioned earlier, despite phosphate-free dialysis, correction of acidosis, and glucose loading with peritoneal dialysis, the plasma PO4--concentration may decrease only slightly if severe secondary hyperparathyroidism and osteitis fibrosa are present. If the Ca++ concentration of the dialysis bath is not significantly below that of the blood, a positive balance of calcium (bath to patient) will occur. Because in most medical centers in the past Ca+ + concentrations in the bath have been maintained between 8 and 10 mg per 100 ml. (4-5 mEq/l), positive Ca++ balance has been the rule. Although the skeleton needs this calcium, the soft tissues do not.
From the above, the optimal theoretical benefit from dialysis would be achieved if Ca++, P04--and HCO3-(blood pH) concentrations returned to normal, and if a "temporary" increased sensitivity to vitamin D and a normal feed back inhibition of parathyroid secretion occurred as Ca++ concentration returned to normal. Circulating PTH levels would then fall and all hormonal and non-hormonal changes would be conducive to recalcification of the skeleton, new bone accretion or formation without enhanced soft tissue deposition. Unfortunately, this ideal correction of the metabolic defects is probably an unusual occurrence. A number of adverse patterns of response may be seen in a chronic dialysis program.
1.) A failure to improve the vitamin D resistance or completely "shut off" the excess PTH secretion. If under these circumstances a negative Ca++ and POJ4-balance is achieved by appropriately low concentrations of Ca++ and P04= in the dialysis bath, soft tissue calcification will be prevented but the demineralization of the skeleton will worsen. Therapeutically adequate doses of vitamin D may correct the osteomalacic component but make the skeleton more responsive to the excess PTH; osteitis fibrosa may then ensue.
2.) If the same result is achieved as in the preceding paragraph, but the Ca++ content of the dialysis bath causes a positive balance with each dialysis, soft tissue deposition of Ca++ salts and metastatic calcification will occur. 40 Volume 40, August, 1967 I)ivaletit ions in renal failure IKLEEMAN, BETTER, MASSRY, MAXWELL 3.) Increased sensitivity to endogenous or exogenous vitamin D, but sustained hypersecretion of PTH, mnay lead to the rapid (weeks) developnment of severe osteitis fibrosa with or without metastatic calcification.
4.) Clhronic dialysis engrafted on a patient who already has overt "autonomous" secondary hyperparathyroidism with or without metastatic calcification, would cause increasingly severe osteitis fibrosa with more transfer of calcium salts from bone to soft tissues. In such a patient, the P04= concentration would tend to decrease less witlh each dialysis and the rise in calcium ion concentration (from bone or dialvsis bath) would b)oth cause more metastatic calcification. The latter may reach enormous proportions. The whole picture could only be aggravated by simultaneous treatment of this patient with therapeutic doses of vitamin D. Finally, correcting metabolic acidosis or, at times, even producing mild-to-moderate alkalosis will enhance the tendency during all of the above to metastatic calcification, the calcium phosphate salts being more insoluble in alkaline mnedia. Unless blood pH is being monitored, the physician may be unaware that alkalosis is present because the HCO3-content of the post-dialysis plasma is not greater than normal. However, chronically uremic patients mnay have mild-to-moderate central hyperventilation.' This may not be corrected by the dialysis. The continued low pCO2 with normal HC03-will result in respiratory alkalosis. In recent years most chronic dialysis centers have been aware of an increasing incidence of band kerotopathy or corneal and conjunctival metastatic calcification in their patients. In the experience of the senior author, one hypercalcemic disorder in which this finding is most common is Burnett's, or the milk-alkali syndrome, or chronic CaCO3 ingestion in peptic ulcer patients. Alkalosis is simultaneously present in almost all these patients.
As patients are being kept alive for longer and longer periods in chronic dialysis programs, all combinations of the above adverse responses are being seen with disturbing frequency. The common denominators of most seem to be the addition of calcium phosphate salts to the soft tissues and the probably continued secretion and/or effects of excess PTH. Avoidance of the latter by parathyroidectomy will generally prevent or correct the former while allowing optimum therapy with vitamin D and exogenous calcium and phosphate salts. It is apparent that total parathyroidectomy or a non-surgical technique (thyrocalcitonin) to block the osseous effects of PTH will become increasingly common in chronic dialysis programs.
While a successful renal transplantation may bring about a total correction of the divalent ion abnormalities and the osteodystrophy, we and others"' g' have seen the development of unequivocal "autonompus" secondary hyperparathyroidism with frank hypercalcemia, hypophosphatemia, very high phosphate clearance, hypercalciuria* and increasingly severe metastatic calcification. The markedly hyperplastic hypersecreting parathyroid glands now in association with relatively normal renal function, cause the development of this syndrome. It is our impression that this syndrome occurs in those patients who demonstrated severe secondary hyperparathyroidism (near normal plasma Ca++, despite elevated PO4-, some osteitis fibrosis, with or without metastatic calcification) prior to renal transplantation.2' This suggests that it would be of benefit before operation to determine, as described above, whether the patient has "autonomously" functioning parathyroid glands.
The syndrome of post-transplantation hyperparathyroidism may appear days, weeks, or months after surgery and we have seen at least one case in whom a moderate syndrome disappeared spontaneously. The latter has also been observed by McIntosh, et al.' and Herdman, et al."1 This spontaneous disappearance of the hyperparathyroid syndrome suggests that in the mild cases with minimal hypercalcemia and no evidence of deterioration in renal function., it may be appropriate to withhold surgery and( follow the patient closely. These patients would seem to be ideal candidates for treatment with inorganic phosphate salts"2 if the latter can correct the hypercalcemia and return the serum PO4-to normal. A theoretical objection to this form of therapy could be that spontaneous disappearance of the hyperparathyroid state may be delayed or prevented by lowering the Ca++ concentration of the blood perfusing these "autonomously" functioning parathyroid glands. It must be remembered that all these post-transplantation cases are taking immuno-suppressive drugs and adrenal glucocorticoids. Consideration must be given to the contribution of this therapy to the disordered calcium and phosphorus metabolism.
In the moderate-to-severe cases of persistent hyperparathyroidism, parathyroidectomy must be done. In contrast to the total parathyroidectomy suggested in the azotemic patient on chronic dialysis patients, we would recommend sub-total removal of 3y2-3-3/4 glands. It is obviously better to attempt to return the post-transplant patient to a euparathyroid state if his renal function is relatively normal.
